{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-037134","form_type":"8-K","ticker":"OM","cik":"0001484612","company_name":"Outset Medical, Inc.","filed_at":"2023-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.055749+00:00","generated_at":"2026-06-12T12:53:03.690948+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Outset Medical Q2 revenue $36M (+44% YoY); pauses TabloCart shipment pending 510(k) clearance","bullets":["Q2 net revenue $36.0M, up 44% YoY; product revenue $29.3M (+49.5%).","Gross margin improved to 21.4% (22.5% non-GAAP) from 15.1% YoY.","Net loss $44.0M ($0.90/share) vs $43.8M ($0.92) YoY.","Paused shipment of TabloCart with Prefiltration pending FDA 510(k) clearance; plans to file later this month.","Reiterated 2023 revenue guidance $144-150M but expects low end due to pause."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-037134","json":"https://secwatch.observer/filing/0000950170-23-037134.json","markdown":"https://secwatch.observer/filing/0000950170-23-037134.md","text":"https://secwatch.observer/filing/0000950170-23-037134.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484612/000095017023037134/0000950170-23-037134-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484612/000095017023037134/om-20230802.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T12:53:03.690948+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2d6450f51b63112e392527891493306fceadaea4","claim":"Outset Medical, Inc. reported the second quarter ended June 30, 2023 results: revenue $36.0 million, net income ($44.0) million, EPS ($0.90) per share. Guidance reaffirmed.","evidence_excerpt":"to reduce the cost and complexity of dialysis, today reported financial results for the second quarter ended June 30, 2023. Recent Highlights • Recorded net revenue of $36.0 million in the second quarter, a 44% increase compared to $25.1 million in the second quarter of 2022, and an 8% increase compared to $33.5 million in the first quarter of 2023. •","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484612/000095017023037134/0000950170-23-037134-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$36.0 million"},{"label":"Net income","value":"($44.0) million"},{"label":"EPS","value":"($0.90) per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}